Daiichi Sankyo Company, Limited (DSKYF)
| Previous close | 37.99 |
| Open | 35.91 |
| Bid | 35.75 x 40000 |
| Ask | 39.35 x 40000 |
| Day's range | 35.91 - 35.91 |
| 52-week range | 23.45 - 40.35 |
| Volume | |
| Avg. volume | 10,548 |
| Market cap | 70.276B |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | 52.81 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.39 (1.08%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | N/A |
- Business Wire
Arbitration Dispute Between Daiichi Sankyo and Seagen Ends
TOKYO & BASKING RIDGE, N.J., June 28, 2024--A dispute between Daiichi Sankyo Co., Ltd. (TSE: 4568) and Seagen Inc. is now concluded and Seagen has paid Daiichi Sankyo approximately U.S. $47 million in connection with attorneys’ fees and costs plus interest awarded by the arbitrator of the party’s dispute.
- Business Wire
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
BASKING RIDGE, N.J. & RAHWAY, N.J., June 26, 2024--The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of Daiichi Sankyo (TSE: 4568) and Merck’s (known as MSD outside of the United States and Canada) (NYSE: MRK) patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with tw
- Business Wire
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
TOKYO & BASKING RIDGE, N.J., June 02, 2024--ENHERTU Demonstrated a Median PFS of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow mBC Following One or More Lines of Endocrine Therapy
